Methods for cellular therapies: tracking cells in-vivo and assessing biodistribution in patients – What are your cells doing? Where do they go?

Cell therapies show great therapeutic promise in the fields of regenerative medicine and immunotherapy. To realize their full clinical potential there is a need for greater understanding of their mode of action, how they migrate after administration to deliver their therapeutic benefits, their persistence at sites of action, and whether their properties, localization or distribution may cause safety issues. Currently, there are several existing and many emerging tools available to develop pharmacokinetic data on these cell-derived therapies to improve our understanding of the mechanism of action and demonstrate on-target delivery, but adoption by clinical investigators has been limited.

In this web seminar, HESI CT-TRACS committee speakers will provide an overview of technologies currently available for use in patients, how these are relevant to evaluate safety and efficacy aspects of cellular therapies, and the importance of collaboration to address challenges and needs facing the translation of cell therapies into the clinic.

1 The Health and Environmental Sciences Institute (HESI) Cell Therapy – TRAcking, Circulation, & Safety (CT-TRACS) committee provides a neutral platform for cell therapy developers, researchers, regulators, imaging specialists and other stakeholders to interact, discuss current challenges and identify best practices to improve confidence in the safety and efficacy of these therapies.


Visit www.pactgroup.net for information on the PACT program.
Methods for cellular therapies:
tracking cells in-vivo and assessing
biodistribution in patients

-Speakers-
Bill Shingleton, BSc, PHD – Alliances Manager, Cytiva
Brooke Helfer, PhD – Director of Research and Development, Celsense, Inc.
David Morrow, PhD, MBA – ATMP and Vaccine Scientific Program Manager, EATRIS

-Objectives-
• Describe available and emerging non-invasive cell tracking modalities and their value in assessing cell fate and safety in vivo.
• Identify the benefits of these technology applications to the clinical translation of cell therapies
• Describe strategies to help translate cell therapies into the clinical setting.
• Outline a process for therapy developers to communicate their challenges and needs that will allow for the development of technologies and tools to address their needs.

-PACT Mission-
Provide assistance for cellular therapy translational research and the manufacture of cellular therapy products for pre-clinical and early phase clinical studies.

Visit www.pactgroup.net for information on the PACT program.

Production Assistance for Cellular Therapies
National Heart Lung and Blood Program

PACT Web Seminar
Please Join Us!
Thursday, September 3, 2020
12:00-1:00 pm ET

Intended Audience:
Scientists, Researchers, Lab Directors, Regulatory Affairs Managers and QA/QC Managers, and Technologists specializing in cell therapy

Fee: No Charge

Registration is open!
Register online at www.pactgroup.net.
Attendees will receive an email detailing audio and web access requirements.

CE INFORMATION:
AMA PRA Category 1 Credits™
ASCLS P.A.C.E. and FL Board of Clinical Laboratory Personnel credit available
see website for details

This project has been funded in whole or in part with Federal funds from the NHLBI, NIH under Contract No. HHSN268201600020C.